文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.

作者信息

Hashmi Hamza, Bachmeier Christina, Chavez Julio C, Song Jinming, Hussaini Mohammad, Krivenko Gabriel, Nishihori Taiga, Kotani Hiroshi, Davila Marco L, Locke Frederick L, Jain Michael D

机构信息

Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.

Division of Hematology Oncology, University of Louisville, Louisville, KY, USA.

出版信息

Br J Haematol. 2019 Oct;187(2):e35-e38. doi: 10.1111/bjh.16155. Epub 2019 Aug 13.

DOI:10.1111/bjh.16155
PMID:31410842
Abstract
摘要

相似文献

[1]
Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.

Br J Haematol. 2019-10

[2]
Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.

Br J Haematol. 2021-8

[3]
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.

Leuk Lymphoma. 2021-7

[4]
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.

Blood Cancer J. 2024-8-12

[5]
Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel.

Br J Haematol. 2022-12

[6]
Diagnostic pitfalls in assessment of ferritin following CAR-T-cell therapy: Understanding the hook effect.

Pediatr Blood Cancer. 2024-9

[7]
[Hemophagocytic lymphohistiocytosis following treatment with CAR-T therapy: two cases reports and literature review].

Zhonghua Xue Ye Xue Za Zhi. 2023-5-14

[8]
Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.

Int Immunopharmacol. 2020-12

[9]
Disseminated toxoplasmosis and haemophagocytic lymphohistiocytosis following chimeric antigen receptor T-cell therapy.

Br J Haematol. 2020-4

[10]
Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia.

Pediatr Blood Cancer. 2021-10

引用本文的文献

[1]
Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

Hematol Oncol Clin North Am. 2025-6

[2]
Influence of CAR T-cell therapy associated complications.

Front Oncol. 2025-2-20

[3]
Advancement and Challenges in Monitoring of CAR-T Cell Therapy: A Comprehensive Review of Parameters and Markers in Hematological Malignancies.

Cancers (Basel). 2024-9-29

[4]
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.

Blood Cancer J. 2024-8-12

[5]
Overview of infectious complications among CAR T- cell therapy recipients.

Front Oncol. 2024-7-3

[6]
CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.

Blood Adv. 2024-6-11

[7]
Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus.

Nat Commun. 2024-3-27

[8]
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).

Blood Adv. 2024-3-26

[9]
Recognizing, defining, and managing CAR-T hematologic toxicities.

Hematology Am Soc Hematol Educ Program. 2023-12-8

[10]
Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.

Hematol Oncol Clin North Am. 2023-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索